[Form 4] DOCUSIGN, INC. Insider Trading Activity
Robert Chatwani, an officer (President General Mgr, Growth) of DocuSign, Inc. (DOCU), reported two open-market sales of Common Stock on 09/17/2025 executed under a Rule 10b5-1 plan. The Form 4 shows a sale of 8,215 shares at prices ranging from $82.20 to $83.18, after which the report lists 76,764 shares beneficially owned. A second sale on the same date of 5,602 shares occurred at prices ranging from $83.20 to $83.65, after which the report lists 71,162 shares beneficially owned. The filing was signed by an attorney-in-fact, and the Reporting Person will provide detailed per-price share counts on request.
- Transaction executed under a Rule 10b5-1 plan, indicating pre-arranged trading and reducing concerns about opportunistic timing
- Full Form 4 disclosure provided with price ranges and post-transaction beneficial ownership figures
- Offer to provide per-price allocation on request increases transparency for regulators and investors
- Executive sold 13,817 shares on 09/17/2025, which may be viewed unfavorably by some investors despite being pre-arranged
- Post-transaction beneficial ownership declined from the higher pre-sale positions (reflected as 76,764 and 71,162 shares after each reported sale)
Insights
TL;DR: Officer sold a modest number of shares under a pre-established Rule 10b5-1 plan; transaction appears routine and disclosed properly.
The Form 4 documents two open-market dispositions by an executive on 09/17/2025 totaling 13,817 shares via an established 10b5-1 plan, with sale prices reported in two ranges between $82.20 and $83.65. The filing provides post-transaction beneficial ownership figures of 76,764 and 71,162 shares respectively and notes availability of per-price allocation on request. From a market-impact perspective, these are disclosed sales rather than option exercises or transfers, and the 10b5-1 framework reduces questions about opportunistic timing.
TL;DR: Disclosure follows standard governance practice; use of attorney-in-fact and 10b5-1 plan increases procedural transparency.
The report names the reporting person and relationship to the issuer, cites a Rule 10b5-1 plan as the execution mechanism, and includes an attorney-in-fact signature, which are all consistent with routine insider transaction governance. The reporting notes precise price ranges and offers detailed allocation upon request, supporting auditability of the trades. No departures from standard Form 4 disclosure norms are evident in the filing.